Medicus has patented minimally invasive drug delivery platform for multibillion dollar markets of lung cancer and other chronic disease.
Medicus has selected lung cancer as the initial market. Each year 160,000 people die of lung cancer in the US and 1.18 million people worldwide. The infrastructure and technical expertise for instilling Medicus’ solution are already in place, paving the way for rapid adoption worldwide. In addition, Medicus has identified a wide range of potential applications including the treatment of mesothelioma, ovarian and bladder cancer, and tuberculosis.